Acumen Pharmaceuticals, Inc.(ABOS)Earnings, Financials & Key Ratios

HYOGO, Japan--(BUSINESS WIRE)--JCR Pharmaceuticals Co., Ltd. (TSE 4552; JCR), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announced that Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) exercised its exclusive option to develop, manufacture, and commercialize, on a global basis, up to two candidates for development in the treatment of Alzheimer's disease (AD), enabled by JCR's proprietary blood-brain barrier (BBB)-penetrating technology platform, J-Brain Cargo®

ACU301 and ACU401 were nominated in the EBD program as part of the exercise of Acumen's option under its license agreement with JCR Pharmaceuticals EBD technology represents the only anti-amyloid oligomer program combining a validated blood-brain barrier-penetrating technology with a therapeutic antibody tested in the clinic Acumen's EBD candidates are designed to achieve higher brain penetration with potential for improved safety compared to native antibodies and delivered in a stable, low volume subcutaneous administration format Investigational New Drug (IND)-enabling activities are ongoing to support IND submission in mid-2027 NEWTON, Mass., June 16, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (Acumen or the Company), a clinical-stage biopharmaceutical company developing novel therapeutics that target soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today announced the nomination of two development candidates in its Enhanced Brain Delivery (EBD) program as treatments for AD.